
Home » Drug & Device Pipeline News
Drug & Device Pipeline News
Company | Drug/Device | Medical Condition | Status |
---|---|---|---|
Trials Authorized | |||
Glenmark Specialty | GRC 54276 | Advanced solid tumors and lymphomas | IND for a phase 1/2 trial approved by the FDA |
Sapience Therapeutics | ST316 | Solid tumors | IND for a phase 1/2 trial approved by the FDA |
Cognition Therapeutics | CT1812 | Geographic atrophy secondary to dry age-related macular degeneration | IND for a phase 2 trial approved by the FDA |
Vivasure Medical | Vivasure PerQseal closure system | Percutaneous vessel closure following percutaneous cardiovascular procedures | IDE approved by the FDA |
Trials Initiated | |||
Bio-Thera Solutions | BAT8007 | Advanced solid tumors | Initiation of a phase 1 trial |
ITM Isotope Technologies | ITM-31 | Malignant glioblastoma | Initiation of a phase 1 trial |
Anaveon | ANV419 | Relapsed/refractory multiple myeloma | Initiation of a phase 1/2 trial |
Alterity Therapeutics | ATH434 | Multiple system atrophy | Initiation of a phase 2 trial |
First Wave BioPharma | Enhanced adrulipase formulation | Exocrine pancreatic insufficiency in patients with cystic fibrosis | Initiation of a phase 2 trial |
Microbion | Topical pravibismane | Moderate chronic diabetic foot ulcer infections | Initiation of a phase 2 trial |
Tonix Pharmaceuticals | TNX-601 ER | Major depressive disorder | Initiation of a phase 2 trial |
Immutep | Eftilagimod alpha plus paclitaxel | Metastatic HER2-/low breast cancer | Initiation of a phase 2/3 trial |
Sermonix Pharmaceuticals | Lasofoxifene plus abemaciclib | Locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation | Initiation of a phase 3 trial |
Approvals | |||
Acadia Pharmaceuticals | Daybue (trofinetide) | Rett syndrome in adults and pediatric patients two and older | Approved by the FDA |
Pfizer | Zavzpret (zavegepant) | Acute treatment of migraines with or without aura | Approved by the FDA |

Upcoming Events
-
06Jun
-
07Jun
-
08Jun